+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, End User - Global Forecast to 2030- Product Image
Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968904
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Plasma Protein Therapeutics Market grew from USD 36.19 billion in 2024 to USD 40.49 billion in 2025. It is expected to continue growing at a CAGR of 11.42%, reaching USD 69.27 billion by 2030.

Pioneering Advances in Plasma Protein Therapeutics

Plasma protein therapeutics have emerged as a transformative cornerstone within modern healthcare, delivering vital treatments for a broad spectrum of conditions. From life-saving albumin infusions for critical care settings to precision-targeted immunoglobulins that shore up immune function, this class of biologics addresses some of the most pressing medical challenges of our time. Fueled by advances in fractionation technologies and robust donor networks, the sector has steadily expanded its portfolio of products and indications over the past decade.

As global healthcare systems contend with aging populations and rising incidence of chronic and immunological disorders, demand for plasma-derived therapies continues to grow. Recent strides in formulation stability, viral inactivation methods, and supply chain integration have further strengthened the reliability and safety profile of these therapies. This introduction sets the stage for a deeper exploration into the market forces, regulatory dynamics, and competitive landscape underpinning the next phase of growth in plasma protein therapeutics.

Emerging Trends Reshaping the Plasma Protein Arena

The plasma protein therapeutics landscape is undergoing transformative shifts driven by innovation, policy evolution, and evolving patient needs. Novel subcutaneous delivery systems have gained traction, offering improved patient compliance compared to traditional intravenous infusion. Concurrently, advancements in purification techniques have enhanced yield and potency, enabling manufacturers to produce higher-concentration formulations that extend shelf life and reduce cold-chain costs.

On the policy front, regulatory agencies worldwide are updating safety guidelines to incorporate new viral clearance standards and manufacturing best practices. This regulatory evolution fosters higher barriers to entry but also ensures greater product consistency and patient safety. Health technology assessment bodies are increasingly evaluating real-world evidence to support reimbursement decisions, reinforcing the importance of robust clinical data and pharmacoeconomic studies. Together, these trends are reshaping competitive priorities, compelling stakeholders to invest in differentiated products and integrated supply chain capabilities.

Assessing the Impact of US Tariffs on Supply Chains

The Cumulative Impact of United States Tariffs 2025 has introduced a new variable into the operational calculus for plasma protein companies. Recent tariff measures on imported plasmaderived raw materials and finished therapeutic products have translated into elevated production costs. Organizations relying on cross-border supply chains face margin pressures as they absorb or pass on tariff increases to downstream stakeholders. This has prompted many to reassess supplier contracts, diversify raw material sourcing, and explore localized fractionation capabilities within US borders.

Simultaneously, pricing negotiations with payers have grown more complex as healthcare providers seek transparency on cost drivers and value-based outcomes. In response, a number of manufacturers have accelerated investments in domestic plasma collection centers to mitigate tariff exposure and reinforce supply resilience. These strategic shifts are expected to recalibrate the competitive equilibrium, with companies demonstrating agile supply chain strategies better positioned to maintain profitable growth amid the evolving tariff landscape.

Decoding Segmentation to Reveal Market Nuances

Comprehensive segmentation analysis reveals distinct growth drivers across product categories, therapeutic indications, delivery routes, and end-user channels. Within product segmentation, albumin formulations are dissected by concentration, encompassing both five-percent neutral solutions and more concentrated twenty-five-percent preparations, each catering to different clinical scenarios. Coagulation factors receive scrutiny across approvals for Factor IX, Factor VIII, and prothrombin complex concentrate, reflecting varying prevalence of hemophilia and acquired bleeding disorders. Hyperimmune globulin subdivisions target niche indications such as hepatitis B, rabies, tetanus, and varicella zoster, with each variant aligned to specific prophylactic and therapeutic use cases. The immunoglobulin segment itself bifurcates into intravenous and subcutaneous administration formats, each offering unique dosing regimens and patient convenience profiles.

Indication segmentation highlights the role of plasma therapeutics in cardiovascular support following major surgery or sepsis, neurological applications for autoimmune neuropathies, and primary and secondary immunodeficiency management. Trauma care remains a critical end market for rapid volume expansion, while off-label explorations continue to emerge.

Regional Dynamics Driving Global Opportunities

Regional dynamics underscore diverse growth trajectories and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas region commands a leading position owing to its well-established plasma donor infrastructure, integrated fractionation capacity, and mature reimbursement environment. In contrast, Europe, Middle East & Africa exhibits heterogeneity in regulatory frameworks and market access protocols, prompting companies to tailor launch strategies country by country. Emerging economies within this region present untapped demand as healthcare investments expand and payer structures evolve.

Asia-Pacific stands out for its rapid growth potential, driven by rising healthcare expenditure, increasing patient awareness of immunodeficiency disorders, and government initiatives to bolster local biologics manufacturing. Regional partnerships and technology transfers are enabling major stakeholders to establish scalable plasma collection networks while navigating complex regulatory landscapes. Together, these regional insights highlight the importance of adaptive market entry strategies, strategic alliances, and compliance agility.

Competitive Intelligence Spotlight

Leading companies are intensifying efforts to secure competitive advantage through vertical integration, portfolio diversification, and strategic collaborations. A global leader in plasma therapeutics has invested heavily in next-generation fractionation facilities while advancing a pipeline of long-acting immunoglobulin formulations. A multinational biologics firm has optimized its plasma collection network in North America and Europe, achieving higher donor retention rates through advanced screening and digital engagement tools. Another key player is forging partnerships with regional manufacturers in Asia-Pacific to accelerate local product registration and production capacity.

These market participants are also deploying data analytics and digital platforms to enhance demand forecasting and streamline distribution. In parallel, targeted acquisitions of specialized biotech ventures have broadened portfolios to include emerging hyperimmune therapies. Strategic alliances with contract manufacturing organizations have further enabled agility in meeting fluctuating demand while maintaining stringent quality standards. This competitive intelligence underscores the criticality of supply chain robustness, R&D agility, and global footprint optimization.

Strategic Imperatives for Industry Leaders

Industry leaders should prioritize investments in domestic manufacturing infrastructure to counteract external tariff pressures and secure supply chain continuity. Expanding plasma collection capabilities through mobile donation units and digital donor outreach can enhance raw material availability while reinforcing brand reputation. Collaborations with academic institutions and contract research organizations can accelerate the clinical validation of novel formulations, strengthening reimbursement dossiers.

To unlock new patient segments, companies should explore hybrid delivery models that combine intravenous initiation with subcutaneous maintenance, improving adherence and lowering administration costs. Engaging with payers early to co-design value-based contracting frameworks will ensure alignment on outcomes and foster sustainable pricing structures. Additionally, forging strategic alliances in high-growth Asia-Pacific markets can fast-track local registration and production, mitigating regulatory barriers. By embracing these actionable imperatives, organizations will be well positioned to navigate evolving market dynamics and capture emerging opportunities in plasma protein therapeutics.

Rigorous Methodology Underpinning the Analysis

This analysis integrates a hybrid methodology combining comprehensive secondary research and targeted primary investigations. Publicly available regulatory filings, clinical trial registries, and company financial disclosures formed the foundation of our secondary data collection. Market trends and industry benchmarks were validated through a series of in-depth interviews with plasma fractionation experts, biotechnology executives, and healthcare economists.

Quantitative analyses included cross-sectional assessment of therapeutic adoption rates, pricing trends, and tariff impacts, while qualitative insights contextualized strategic responses from leading companies. Data triangulation ensured consistency across multiple sources, and all findings underwent rigorous quality control checks to uphold analytical integrity. This robust research framework delivers a holistic view of market dynamics, enabling decision-makers to base strategies on reliable, multi-dimensional evidence.

Concluding Insights and Strategic Outlook

The plasma protein therapeutics market is poised at a critical inflection point, shaped by technological innovation, regulatory evolution, and shifting geopolitical factors. As industry stakeholders navigate tariff realignments and supply chain complexities, the capacity to adapt manufacturing footprints and cultivate resilient donor networks will determine competitive positioning. At the same time, segment-specific growth in high-value immunoglobulins and specialty hyperimmune products underscores the importance of targeted R&D investments.

Regional disparities in infrastructure and reimbursement pathways necessitate nuanced market entry approaches, while the competitive landscape rewards integrated, data-driven organizations. By synthesizing segmentation insights, regional dynamics, and company strategies, this report equips decision-makers with a clear roadmap to drive sustained growth and differentiation. The conclusions drawn here lay the groundwork for strategic planning and investment prioritization in the evolving plasma protein therapeutics ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product
    • Albumin
      • Five Percent
      • Twenty Five Percent
    • Coagulation Factor
      • Factor IX
      • Factor VIII
      • Prothrombin Complex Concentrate
    • Hyperimmune Globulin
      • Hepatitis B
      • Rabies
      • Tetanus
      • Varicella Zoster
    • Immunoglobulin
      • Intravenous Immunoglobulin
      • Subcutaneous Immunoglobulin
  • Indication
    • Cardiovascular
    • Neurological
    • Primary Immunodeficiency
    • Secondary Immunodeficiency
    • Trauma
  • Route Of Administration
    • Intramuscular
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Clinics
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • LFB Group
  • Biotest AG
  • GC Biopharma Co., Ltd.
  • ADMA Biologics, Inc.
  • Bio Products Laboratory Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Plasma Protein Therapeutics Market, by Product
8.1. Introduction
8.2. Albumin
8.2.1. Five Percent
8.2.2. Twenty Five Percent
8.3. Coagulation Factor
8.3.1. Factor IX
8.3.2. Factor VIII
8.3.3. Prothrombin Complex Concentrate
8.4. Hyperimmune Globulin
8.4.1. Hepatitis B
8.4.2. Rabies
8.4.3. Tetanus
8.4.4. Varicella Zoster
8.5. Immunoglobulin
8.5.1. Intravenous Immunoglobulin
8.5.2. Subcutaneous Immunoglobulin
9. Plasma Protein Therapeutics Market, by Indication
9.1. Introduction
9.2. Cardiovascular
9.3. Neurological
9.4. Primary Immunodeficiency
9.5. Secondary Immunodeficiency
9.6. Trauma
10. Plasma Protein Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Plasma Protein Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
12. Americas Plasma Protein Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Plasma Protein Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Plasma Protein Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. CSL Limited
15.3.2. Grifols, S.A.
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. Octapharma AG
15.3.5. Kedrion S.p.A.
15.3.6. LFB Group
15.3.7. Biotest AG
15.3.8. GC Biopharma Co., Ltd.
15.3.9. ADMA Biologics, Inc.
15.3.10. Bio Products Laboratory Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PLASMA PROTEIN THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PLASMA PROTEIN THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PLASMA PROTEIN THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 60. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 61. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 62. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 63. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 69. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 109. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 110. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 111. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 112. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 117. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 118. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 119. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 120. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 133. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 134. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 135. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 136. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 141. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 142. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 143. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 144. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 173. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 174. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 175. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 176. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 188. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 189. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 190. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 191. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 192. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 196. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 197. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 198. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 199. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 200. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 220. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 221. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 222. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 223. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 224. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 228. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 229. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 230. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 231. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 232. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 244. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 245. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 246. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 247. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 248. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 252. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 253. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 254. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 255. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 256. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 277. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 278. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 279. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 280. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 281. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 285. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 286. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 287. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 288. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 289. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 293. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 294. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 295. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 296. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 297. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 298. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDON

Companies Mentioned

The companies profiled in this Plasma Protein Therapeutics market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • LFB Group
  • Biotest AG
  • GC Biopharma Co., Ltd.
  • ADMA Biologics, Inc.
  • Bio Products Laboratory Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 40.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 69.27 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Plasma Protein Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Plasma Protein Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Plasma Protein Therapeutics - Global Strategic Business Report - Product Image

Plasma Protein Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Plasma Protein Therapeutics Market Report 2025 - Product Image

Plasma Protein Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Plasma Protein Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Plasma Protein Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 96 Pages
  • Global
From
Protein Therapeutics Market by Modality, Therapeutic Area, Route of Administration, Dosage Form, End User - Global Forecast to 2030 - Product Image

Protein Therapeutics Market by Modality, Therapeutic Area, Route of Administration, Dosage Form, End User - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From

About the Plasma Protein Drug Market

The Plasma Protein Drug market is a subset of the biopharmaceutical industry, focusing on the development and production of drugs derived from human plasma proteins. These drugs are used to treat a variety of conditions, including immune deficiencies, bleeding disorders, and other rare diseases. Plasma protein drugs are typically produced through fractionation, a process that separates the proteins from the plasma. This process is used to create a variety of products, including albumin, immunoglobulins, and clotting factors. The Plasma Protein Drug market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products. Additionally, the market is highly competitive, with a number of companies vying for market share. Some of the major players in the Plasma Protein Drug market include CSL Behring, Grifols, Octapharma, Kedrion, and Biotest. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.